GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BSF Enterprise PLC (OTCPK:BSFAF) » Definitions » Total Receivables

BSFAF (BSF Enterprise) Total Receivables : $0.11 Mil (As of Sep. 2024)


View and export this data going back to 2023. Start your Free Trial

What is BSF Enterprise Total Receivables?

BSF Enterprise's Total Receivables for the quarter that ended in Sep. 2024 was $0.11 Mil.


BSF Enterprise Total Receivables Historical Data

The historical data trend for BSF Enterprise's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BSF Enterprise Total Receivables Chart

BSF Enterprise Annual Data
Trend Sep19 Sep20 Sep21 Sep22 Sep23 Sep24
Total Receivables
Get a 7-Day Free Trial - - 0.09 0.11 0.11

BSF Enterprise Semi-Annual Data
Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.09 3.53 0.11 0.10 0.11

BSF Enterprise Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables


BSF Enterprise Total Receivables Related Terms

Thank you for viewing the detailed overview of BSF Enterprise's Total Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


BSF Enterprise Business Description

Traded in Other Exchanges
Address
2 Portman Street, London, GBR, W1H 6DU
BSF Enterprise PLC is a United Kingdom-based biotech company. The Company is focused on developing biotechnological solutions using cell-based tissue engineering to help generate cultured meat, lab-grown leather, as well as human corneas, collagen growth and skin substitutes. The Company operates through its wholly owned subsidiary, 3D Bio-Tissues Limited (3DBT), which is a clinical and cellular agriculture company engaged in producing human corneas that could help restore vision to millions of people.

BSF Enterprise Headlines

From GuruFocus